Johnson & Johnson reportedly plans to dump its entire stake in Achillion Pharmaceuticals through a public offering.
Marijuana could be a game-changer for this deadly neurodegenerative disorder.
Celgene Corp., Juno Therapeutics, and Cara Therapeutics are three biotech stocks to watch in 2018.
Puma's shares are starting to give ground as Nerlynx's highly anticipated commercial launch gets underway in earnest.
Intrexon's shares nosedived today on a worse-than-expected third-quarter earnings release.
The company's pursuit of two megablockbuster vaccine candidates makes it a viable comeback candidate.
Five Prime Therapeutics and Bristol-Myers Squibb may have a viable pancreatic cancer drug after all.
Amazon's potential entrance into the retail pharmacy space sent Rite Aid's shares reeling last month.
Spectrum's preliminary lung cancer data sparked a noteworthy rally in its shares last month.
Inovio fell victim to the biotech exodus last month.
Valeant takes another major step towards addressing its debt problem.
Investors bid up this gene-editing company last month, but that doesn't mean it's time to buy.
Investors are growing impatient with Celldex's slow but steady march to its next major data release.
Allergan's stock slips for the third straight month in October.
MannKind's stock caught fire last month, but its positive momentum may be short-lived.
If you're on the hunt for companies developing game-changing medical technologies, Apple, Bellicum Pharmaceuticals, and Novocure need to be on your radar.
Geron and Johnson & Johnson's experimental blood-cancer drug may end up living up to the hype after all.
TransEnterix's shares are on the mend today, thanks to the buyout-rumor mill and an analyst upgrade.
These three foreign dividend stocks could be great buys right now. Here's why.
Celgene and GlaxoSmithKline hit the skids last week. Is it time to buy?